Skip to content

Journal Club

Quarterly Review of Publications by the GEST Research Committee


Join GEST’s Research Committee as we review current publications and breakthrough research that can impact IR’s practice and patient outcomes. The Journal Club will meet virtually online once per quarter. To view past discussions, click here

June 4, 2024 | 5-6 pm EST

Join GEST for a one-hour review of “Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial”.

The Partem trial is the first trial comparing Medical therapy to PAE. It was lead by Pr Marc Sapoval, MD PhD GEST founder and published in the Lancet.

It reflects the collaborative efforts of 10 centers where urologists and Interventional Radiologist are working together.

The positive outcome allows to propose PAE in case of failure of Alpha-blockers treatment in patients with BPH > 50 ml.


  • Dr. Marc Sapoval, Hôpital Européen Georges-Pompidou
  • Dr. Michael Borofsky, University of Minnesota
  • Dr. Shivank Bhatia, University Of Miami Miller School Of Medicine
  • Dr. Nassir Rostambeigi, Washington University School of Medicine
GEST Journal Club

June Journal Club Faculty

Marc Sapoval

Dr. Marc Sapoval

Hôpital Européen Georges-Pompidou

Michael Borofsky

Dr. Michael Borofsky

University of Minnesota

Shivank Bhatia

Dr. Shivank Bhatia

University Of Miami Miller School Of Medicine

Nassir Rostambeigi

Dr. Nassir Rostambeigi​

Washington University School of Medicine

The June Journal Club is Sponsored by



GEST Education

The GEST Group has developed premiere events including the annual GEST conference, focused topic meetings and summits where physicians come to learn from other physicians in the field of embolization.

Past Journal Club Topics

EPOCH (Evaluating TheraSphere in Patients with metastatic colorectal carcinoma Of the liver who have progressed on first-line Chemotherapy) is the first study to investigate the role of transarterial radioembolization with Yttrium-90 (TARE) when added to standard-of-care second-line chemotherapy for colorectal liver metastases.

Join the Journal Club on March 19th to listen to Dr Riad SALEM ‘s presentation of the study and its results on delayed disease progression, and, with our experts panel, follow the discussion of subset analyses to better identify the ideal patients who could benefit most, as well as dosimetric considerations to optimize the risk-benefit profile of TARE exposure.

Physician Faculty: 

  • Dr. Shamar Young, University of Arizona
  • Dr. Beau Toskich, Mayo Clinic
  • Dr. Mohammad Khreiss, University of Arizona
  • Dr. Riad Salem, Feinberg School of Medicine
  • Dr. Sudhir Manda, Arizona Oncology

On-demand Button

Educational Grant provided by Boston Scientific